Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · December 19, 2023

Efficacy and Safety of Ligelizumab for the Treatment of Adults and Adolescents With Chronic Spontaneous Urticaria

The Lancet

 

Additional Info

The Lancet
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
Lancet 2023 Nov 23;[EPub Ahead of Print], M Maurer, LF Ensina, AM Gimenez-Arnau, G Sussman, M Hide, S Saini, C Grattan, D Fomina, D Rigopoulos, F Berard, GW Canonica, H Rockmann, C Irani, JC Szepietowski, J Leflein, JA Bernstein, JG Peter, K Kulthanan, K Godse, L Ardusso, O Ukhanova, P Staubach, R Sinclair, S Gogate, SF Thomsen, T Tanus, YM Ye, A Burciu, A Barve, D Modi, E Scosyrev, E Hua, K Letzelter, V Varanasi, M Patekar, T Severin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading